Acute Coronary Syndrome (ACS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Acute Coronary Syndrome (ACS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Acute Coronary Syndrome (ACS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global ACS therapeutics market. The report identifies the key trends shaping and driving the global ACS therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global ACS sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).

Scope

The report provides information on the key drivers and challenges of the ACS therapeutics market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) ACS therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Factor Xa inhibitors, P2Y (12) receptor antagonists, platelet aggregation inhibitors, CETP inhibitors and ADP receptor antagonists.
- Analysis of the current and future competition in the global TBI market. Key market players covered GlaxoSmithKline, The Medicine Company, Sanofi, Bayer AG/ Johnson & Johnson (J&J), F. Hoffmann-La Roche, Anthera Pharmaceuticals, Portola Pharmaceuticals/Novartis AG and Eisai Co., Ltd.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the ACS therapeutics market.
- Analysis of key recent licensing and partnership agreements in ACS therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global ACS therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global ACS therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global sepsis therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 7
2 Acute Coronary Syndrome (ACS) Therapeutics Market: Executive Summary 9
2.1 The ACS Therapeutics Market is Estimated to grow at a Compound Annual Growth Rate (CAGR) of 0.6% from 2010 to 2018 9
2.2 Current Competition in the ACS Therapeutics Market is Weak 10
2.3 High Unmet Needs Exist in the ACS Therapeutics Market in terms of Efficacy and Safety can be Addressed by Strong Pipeline with Many Novel First-in-class Molecules 12
2.4 Late Stage Development Failure Poses Threat to Market Growth 12
3 ACS Therapeutics: Introduction 13
3.1 Overview 13
3.1.1 ACS classification - 13
3.2 Epidemiology 14
3.3 Etiology 15
3.4 Symptoms 16
3.5 Diagnosis 16
3.5.1 12-lead ECG 17
3.5.2 Biomarkers 18
3.5.3 Chest Pain Observation Protocols 19
3.5.4 Imaging techniques 19
3.6 Treatment Algorithm of ACS 20
3.6.1 Treatment for the Symptoms of ACS – 21
3.6.2 Treatment for the Cause of ACS 21
3.6.3 Primary and Secondary Prevention 24
3.7 GlobalData Pipeline Report Guide 29
4 ACS Therapeutics: Market Characterization 31
4.1 Overview 31
4.2 ACS Therapeutics Market Size (2005-2010) – Global 31
4.3 ACS Therapeutics Market Forecast (2010-2018) – Global 33
4.4 ACS Therapeutics Market – The US (2005-2010) 34
4.5 ACS Therapeutics Market Forecast – The US (2010-2018) 35
4.6 ACS Therapeutics Market – France (2005-2010) 37
4.7 ACS Therapeutics Market Forecast – France (2010-2018) 38
4.8 ACS Therapeutics Market – Germany (2005-2010) 39
4.9 ACS Therapeutics Market Forecast - Germany (2010-2018) 40
4.10 ACS Therapeutics Market – Italy (2005-2010) 41
4.11 ACS Therapeutics Market Forecast – Italy (2010-2018) 42
4.12 ACS Therapeutics Market – Spain (2005-2010) 44
4.13 ACS Therapeutics Market Forecast – Spain (2010-2018) 45
4.14 ACS Therapeutics Market – The UK (2005-2010) 46
4.15 ACS Therapeutics Market Forecast – The UK (2010-2018) 48
4.16 ACS Therapeutics Market - Japan (2005-2010) 49
4.17 ACS Therapeutics Market Forecast – Japan (2010-2018) 50
4.18 Drivers and Barriers for the Acute Coronary Syndrome Market 51
4.18.1 Drivers for the ACS Therapeutics Market 52
4.18.2 Barriers for the ACS Therapeutics Market 53
4.19 Opportunity and Unmet Need 53
4.20 Key Takeaway 56
5 ACS Therapeutics: Competitive Assessment 57
5.1 Overview 57
5.2 Strategic Competitor Assessment 57
5.3 Product Profile for the Major Marketed Products in the ACS Therapeutics Market 58
5.3.1 Nitrates 58
5.3.2 Beta-adrenergic Receptor Blockers (Beta Blockers) 59
5.3.3 Calcium Channel Blockers 60
5.3.4 Angiotensin Converting Enzyme Inhibitor (ACE inhibitors) 60
5.3.5 Statins 61
5.3.6 Glycoprotein IIb/IIIa inhibitor 63
5.3.7 Lovenox (enoxaparin sodium injection) 69
5.3.8 Plavix (clopidogrel bisulfate) 71
5.3.9 Effient (prasugrel) 73
5.3.10 Brilinta (ticagrelor) 76
5.4 Key Takeaway 80
6 ACS Therapeutics: Pipeline Assessment 81
6.1 Overview 81
6.2 Strategic Pipeline Assessment 81
6.3 ACS Therapeutics Market – Promising Drugs under Clinical Development 85
6.4 Molecule Profile for Promising Drugs under Clinical Development 86
6.4.1 A-002 (varespladib Methyl) 86
6.4.2 Darapladib (SB-480848) 87
6.4.3 Dalcetrapib (RO4607381/Jtt-705) 89
6.4.4 Xarelto (rivaroxaban) 90
6.4.5 Otamixaban 91
6.4.6 Elinogrel 91
6.4.7 Cangrelor 93
6.5 ACS Therapeutics Market – Clinical Pipeline by Mechanism of Action 94
6.5.1 ACS Therapeutics – Phase III Clinical Pipeline 96
6.5.2 ACS Therapeutics – Phase II Clinical Pipeline 97
6.5.3 ACS Therapeutics – Phase I Clinical Pipeline 97
6.5.4 ACS Therapeutics – Discovery and Preclinical Pipeline 97
6.6 Key Takeaway 98
7 ACS Therapeutics: Clinical Trials Mapping 99
7.1 Clinical Trials by Region/Country (the US, EU5 & Japan) 99
7.2 Clinical Trials by Phase of Clinical Development 100
7.3 Clinical Trials by Trial Status 101
7.4 Clinical Trials by Sponsors 102
7.5 Brief Profiles of Top 10 Companies Participating in Clinical Trials 104
8 ACS Therapeutics: Strategic Assessment 106
8.1 Key Events Impacting the Future Market 106
8.2 Future Market Competition Scenario 106
9 ACS Therapeutics: Future Players 109
9.1 Introduction 109
9.1.1 GlaxoSmithKline Plc 109
9.1.2 F. Hoffmann-La Roche 111
9.1.3 Anthera Pharmaceuticals 112
9.1.4 Novartis A G 112
9.1.5 Sanofi 114
9.1.6 Johnson & Johnson 115
9.1.7 Bayer AG 116
9.1.8 The Medicines Company 118
9.1.9 Eisai Co., Ltd. 120
9.1.10 Portola Pharmaceuticals, Inc. 123
9.1.11 Tabular Presentation Details of Other Companies in the Pipeline 124
10 ACS Therapeutics: Licensing and Partnership Deals 128
11 ACS Therapeutics: Appendix 130
11.1 Definitions 130
11.2 Acronyms 130
11.3 Methodology 131
11.3.1 Coverage 131
11.3.2 Secondary Research 132
11.3.3 Forecasting 132
11.3.4 Primary Research 135
11.3.5 Expert Panel Validation 136
11.4 Contact Us 136
11.5 Disclaimer 136
11.6 Bibliography 137